Profile of elotuzumab and its potential in the treatment of multiple myeloma

by Liu, Yi-Chang, Szmania, Susann, van Rhee, Frits
Published 2014

A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease

by van Rhee, Frits, Casper, Corey, Voorhees, Peter M., Fayad, Luis E., van de Velde, Helgi, Vermeulen, Jessica, Qin, Xiang, Qi, Ming, Tromp, Brenda, Kurzrock, Razelle
Published 2015

Patient-reported Outcomes for Multicentric Castleman’s Disease in a Randomized, Placebo-controlled Study of Siltuximab

by van Rhee, Frits, Rothman, Margaret, Ho, Kai Fai, Fleming, Sarah, Wong, Raymond S., Fosså, Alexander, Dispenzieri, Angela, Cavet, James, Munshi, Nikhil, Vermeulen, Jessica, Casper, Corey
Published 2015

Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols

by Singh, Zeba N, Jethava, Yogesh, Post, Ginell R, Alapat, Daisy, Sawyer, Jeffrey, Waheed, Sarah, Nair, Bijay, Usmani, Saad Z, Bailey, Clyde, Petty, Nathan, Van Rhee, Frits, Barlogie, Bart
Published 2015

Interleukin-6 Receptor Polymorphism Is Prevalent in HIV-negative Castleman Disease and Is Associated with Increased Soluble Interleukin-6 Receptor Levels

by Stone, Katie, Woods, Emily, Szmania, Susann M., Stephens, Owen W., Garg, Tarun K., Barlogie, Bart, Shaughnessy, John D., Hall, Brett, Reddy, Manjula, Hoering, Antje, Hansen, Emily, van Rhee, Frits
Published 2013

Characterization of the Molecular Mechanism of the Bone-Anabolic Activity of Carfilzomib in Multiple Myeloma

by Hu, Bo, Chen, Yu, Usmani, Saad Z., Ye, Shiqiao, Qiang, Wei, Papanikolaou, Xenofon, Heuck, Christoph J., Yaccoby, Shmuel, Williams, Bart O., Van Rhee, Frits, Barlogie, Bart, Epstein, Joshua, Qiang, Ya-Wei
Published 2013

Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling, and clinical outcome with Total Therapy protocols

by Usmani, Saad Z, Nair, Bijay, Qu, Pingping, Hansen, Emily, Zhang, Qing, Petty, Nathan, Waheed, Sarah, Shaughnessy, John D, Alsayed, Yazan, Heuck, Christoph J, van Rhee, Frits, Milner, Teresa, Hoering, Antje, Szymonifka, Jackie, Sexton, Rachael, Sawyer, Jeffrey, Singh, Zeba, Crowley, John, Barlogie, Bart
Published 2012

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia

by Boyiadzis, Michael, Bishop, Michael R., Abonour, Rafat, Anderson, Kenneth C., Ansell, Stephen M., Avigan, David, Barbarotta, Lisa, Barrett, Austin John, Van Besien, Koen, Bergsagel, P. Leif, Borrello, Ivan, Brody, Joshua, Brufsky, Jill, Cairo, Mitchell, Chari, Ajai, Cohen, Adam, Cortes, Jorge, Forman, Stephen J., Friedberg, Jonathan W., Fuchs, Ephraim J., Gore, Steven D., Jagannath, Sundar, Kahl, Brad S., Kline, Justin, Kochenderfer, James N., Kwak, Larry W., Levy, Ronald, de Lima, Marcos, Litzow, Mark R., Mahindra, Anuj, Miller, Jeffrey, Munshi, Nikhil C., Orlowski, Robert Z., Pagel, John M., Porter, David L., Russell, Stephen J., Schwartz, Karl, Shipp, Margaret A., Siegel, David, Stone, Richard M., Tallman, Martin S., Timmerman, John M., Van Rhee, Frits, Waller, Edmund K., Welsh, Ann, Werner, Michael, Wiernik, Peter H., Dhodapkar, Madhav V.
Published 2016